ProBioGen Delivers Strong 2022 Performance, Investing for Growth in 2023

Berlin, Germany – March 30, 2023

ProBioGen, the Berlin-based CDMO and technology provider, reported today that revenues for the fiscal year 2022 (FY22) grew 35% vs FY21.

In a year marked by new geopolitical and macroeconomic challenges, ProBioGen was able to carry on its rapid growth trajectory by completing a significantly increased number of projects. To support this influx of activities, ProBioGen recruited more than 80 new talents to close 2022 with over 300 employees and moved on in its full digital transformation process aiming at making IT not only a supporting operative function but also a decisive function in the innovation process.

"I am proud of the solid performance ProBioGen delivered in 2022, reaching new heights after an already very successful 2021. I would like to warmly thank all employees for their dedication and hard work which rendered this possible. I also believe that the 2030 Strategic Roadmap we developed in the second half of 2020 has put ProBioGen in the right direction and proven its resilience in difficult times", said Dr. Lutz Hilbrich, Chief Executive Officer at ProBioGen and MiGenTra.

The strong growth is attributable to numerous new customer projects as well as to an increased repeat business with highly satisfied customers. According to customer feedback, ProBioGen's deep scientific expertise as well as the flexible project approach make the company stand out.

Looking at 2023, ProBioGen will keep investing for its future despite a continued gloomy global economic outlook, focusing its attention to broadening its service and technology offering to meet the needs of a broader base of customers and further enhance its competitive edge.

About ProBioGen

ProBioGen is a Berlin-based biotech company and Contract Development and Manufacturing Organization (CDMO) and technology provider that operates globally.

It specializes in developing and manufacturing biopharmaceutical active ingredients, viral vectors and vaccines, applying proprietary technologies to improve product quality and features. It started in 1994 as a spin-off of Charité, a widely recognized hospital as one of the best in the world. Twenty-eight years later, over 300 employees work at ProBioGen's three locations in Berlin.

Every day, they contribute to the creation of new therapies in medicine and groundbreaking innovations worldwide through their creative and meticulous work. ProBioGen's growth strategy is driven by the expansion of the service value chain through organic growth and potential acquisition. Diversification is a complement driver, while the focus is strict on enabling the development of biopharmaceuticals for tomorrow.

For more information about ProBioGen, follow us on LinkedIn.

ProBioGen Contact:

Dr. Gabriele Schneider
Chief Business Officer

Go back